JSM 2015 Preliminary Program

Online Program Home
My Program

Abstract Details

Activity Number: 449
Type: Contributed
Date/Time: Tuesday, August 11, 2015 : 2:00 PM to 2:45 PM
Sponsor: Biopharmaceutical Section
Abstract #317791
Title: Quality-Adjusted Survival Analysis: An Application to a Phase III Randomized Study in Multiple Myeloma
Author(s): Suddhasatta Acharyya* and Ashok Panneerselvam and Sofia Paul
Companies: Novartis Pharmaceuticals and Novartis Pharmaceuticals and Novartis Pharmaceuticals
Keywords: survival ; quality-of-life ; oncology ; risk-benefit
Abstract:

The critical question, in the context of confirmatory oncology drug trials is whether we have a clear answer on the risk-benefit ratio. A comprehensive metric that combines both efficacy and safety endpoints, as well as, patient-reported quality of life endpoints could be very useful in this context. A popular approach is to use a modified overall survival type analysis, where, instead of the usual survival time, a 'quality-adjusted' version of it is analyzed. One such measure is the Q-TWiST, which may be described as the 'quality-adjusted time without symptoms and toxicity'. Originally, QTWiST was developed for the adjuvant setting but has since been extended in several directions. Here, we adapt the QTWiST methodology to our specific situation, which is a two-arm randomized phase III oncology study, in multiple myeloma. While the Q-TWiST methodology itself is fairly well-developed, its application to specific datasets often brings up analytical issues, some of which will be touched upon, as they apply to our study.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2015 program





For program information, contact the JSM Registration Department or phone (888) 231-3473.

For Professional Development information, contact the Education Department.

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.

2015 JSM Online Program Home